Drug Trial Radar · NCT07742215
A Study of the Efficacy and Safety of BCD-248 in Combination With Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma (AMMADINA)
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
Jun 15, 2026
Primary completion
Jul 2028
Study completion Oct 2032
Sponsor
- Lead sponsor
- BiocadIndustry
- Sponsor type
- Industry
- First posted
- Aug 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of the study is to assess the efficacy and safety of the BCD-248 in combination with daratumumab versus the combination of daratumumab, pomalidomide, and dexamethasone in the treatment of relapsed or refractory multiple myeloma. The study will be conducted in a population of male and female subjects aged 18 years and older, with confirmed symptomatic multiple myeloma with measurable disease, who have received one prior line of therapy that included a proteasome inhibitor and lenalidomide and were refractory to lenalidomide, or who have received two or three prior lines of therapy that included a proteasome inhibitor and lenalidomide, with disease progression during or after the last line of therapy.
Conditions
- Myeloma Multiple
Interventions
BCD-248 + daratumumabDrug
BCD-248 subcutaneously, daratumumab intravenously
Daratumumab + pomalidomide + dexamethasoneDrug
Daratumumab intravenously, pomalidomide per os, dexamethasone per os
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of MRD negativity by flow cytometry at 12 months from the start of therapyTime frame: up to 12 months
- Progression-free survival according to the International Myeloma Working Group (IMWG) criteriaTime frame: up to 36 months
Locations
16 sites in 2 countries. Site status is shown where the registry gives one.
SI "Republican Scientific and Practical Center for Radiation Medicine and Human Ecology"
Homyel, Belarus · Recruiting
SBHI "Chelyabinsk regional clinical hospital"
Chelyabinsk, Russia · Recruiting
SBHI "Regional oncological dispensary"
Irkutsk, Russia · Recruiting
SAHI "Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan named after Professor M.Z. Sigal"
Kazan', Russia · Recruiting
Regional Government-Owned Publicly Funded Healthcare Institution "Regional Clinical Hospital"
Krasnoyarsk, Russia · Recruiting
Branch Office of Hadassah Medical Ltd.
Moscow, Russia · Recruiting
BHI of the Omsk region "Clinical Oncological Dispensary"
Omsk, Russia · Recruiting
St. Petersburg State Healthcare Institution "City Hospital No. 15"
Saint Petersburg, Russia · Recruiting
FSBI "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation
Saint Petersburg, Russia · Recruiting
FSBI "Russian Research Institute of Hematology and Transfusiology" of the Federal Medical and Biological Agency
Saint Petersburg, Russia · Recruiting
SBHI "Leningrad Regional Clinical Hospital"
Saint Petersburg, Russia · Recruiting
FSBEI of Higher Education "Samara State Medical University" of the Ministry of Health of the Russian Federation
Samara, Russia · Recruiting
FSBEI HE "Saratov State Medical University named after V.I. Razumovsky" of the Ministry of Health of Russia
Saratov, Russia · Recruiting
Private healthcare institution "Clinical hospital "RZD-Medicine" of the city of Smolensk"
Smolensk, Russia · Recruiting
State Budgetary Healthcare Institution "Oncological Dispensary No.2" of the Ministry of Health of the Krasnodar Region
Sochi, Russia · Recruiting
SBHI "Republican Clinical Hospital named G.G. Kuvatov"
Ufa, Russia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.